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Unprecedented developments in stem cell research herald a new era of hope and expectation for novel ther-
apies. However, they also present amajor challenge for regulators since safety assessment criteria, designed
for conventional agents, are largely inappropriate for cell-based therapies. This article aims to set out the
safety issues pertaining to novel stem cell-derived treatments, to identify knowledge gaps that require further
research, and to suggest a roadmap for developing safety assessment criteria. It is essential that regulators,
pharmaceutical providers, and safety scientists work together to frame new safety guidelines, based on
‘‘acceptable risk,’’ so that patients are adequately protected but the safety ‘‘bar’’ is not set so high that
exciting new treatments are lost.Immense expectation surrounds the area of stem cell therapeu-
tics. Pressures are building to accelerate their development,
from patients requiring effective therapy as well as companies
requiring new products for dwindling pipelines and needing to
diversify portfolios. This anticipation is independent of the
source of stem cells (adult versus embryonic, or patient-derived
autologous cells versus healthy donor adult or embryonic allo-
geneic cells). However, as with all new treatments, our knowl-
edge about the safety of these medicinal products is still limited
and needs to be expanded to assess their therapeutic safety
more effectively. The purpose of this article (which arose from
discussions at a workshop hosted by the MRC Center for
Drug Safety Science in Liverpool) is to outline the major safety
issues associated with stem cell therapeutics, to identify the
gaps in our knowledge with respect to these issues, and to
propose a set of recommendations designed to facilitate the
development and clinical application of stem cell therapies
from an industrial, clinical, and regulatory perspective. In
2008, the ISSCR published a detailed set of guidelines for the
translation of stem cell research into clinical practice (Hyun
et al., 2008). While there is some overlap in the issues ad-
dressed by both publications, the current article focuses
specifically on the broader principles associated with the safe
use of stem cell therapies and is intended to complement the
ISSCR guidelines.618 Cell Stem Cell 8, June 3, 2011 ª2011 Elsevier Inc.Current Status of StemCell Therapeutics and the Safety
Challenge
Since they were first isolated by James Thomson (Thomson
et al., 1998), the capacity of human embryonic stem cells
(hESCs) for potentially unlimited self-renewal and differentiation
has led to many attempts to exploit them in drug discovery,
disease modeling, and regenerative medicine (Koay et al.,
2007; Perin et al., 2008; Wong and Bernstein, 2010; Zaret and
Grompe, 2008). Attempts are underway to differentiate hESCs
into inter alia, hepatocytes (Baxter et al., 2010; Cai et al., 2007;
Duan et al., 2007; Hay et al., 2008; Sullivan et al., 2010; Touboul
et al., 2010; Vallier, 2011; Bone et al., 2011), cardiomyocytes (Ke-
hat et al., 2001; Passier et al., 2005), neurones (Schuldiner and
Benvenisty, 2003; Zhang et al., 2001), and intestinal tissue
(Spence et al., 2011). Several pluripotent and multipotent stem
cell-based therapeutics have entered clinical trials. Table 1
shows a summary of selected stem cell-based therapeutics
approved for clinical trials by the United States Food and Drug
Administration (FDA) or the UK Medicines and Healthcare Prod-
ucts Regulatory Agency (MHRA) to treat injuries to the central
nervous system, myocardial infarction, and diabetes. Clearly,
the explosive growth in interest in the use of induced pluripotent
stem cells (iPSCs) opens up novel avenues of therapeutic devel-
opment based on adult stem cells, thereby avoiding some of the
ethical issues surrounding the use of human embryos to derive
Table 1. Selected Pluripotent and Multipotent Stem Cell-Based Therapeutics Currently Undergoing Clinical Trials in the US and UK
Condition Intervention Sponsor Study Design
Sample
size Inclusion Criteria Time Frame Reference
Spinal cord
injury (SCI)
GRNOPC1:
oligodendrocyte
progenitor cells
Geron Corp. Non-randomized,
single arm,
uncontrolled
10 18–65 years, M+F.
Neurologically complete,
traumatic SCI. Single
lesion
12 months http://clinicaltrials.gov/ct2/show/
NCT01217008?term=GRNOPC1&rank=1
Stable ischemic
stroke (IS)
CTX0E03:
neural stem cells
ReNeuron Ltd. Non-randomized,
single administration,
ascending dose
12 M, > 60. Unilateral IS,
> 1cm infarction. NIHSS
minimum 6
2 year monitoring.
8 year follow-up
trial
http://clinicaltrials.gov/ct2/show/
NCT01151124?term=ctx0e03&rank=1
Acute myocardial
infarction (AMI)
AMI MultiStem Athersys Inc. Non-randomized control
and treatment groups.
3 dose escalation cohorts
28 18–80 years,
M+F. 1st time
diagnosis of
ST-elevated AMI
Adverse events
during 24 hr.
Postacute events
30 days. 12 month
follow-up
http://clinicaltrials.gov/ct2/show/
NCT00677222?term=multistem&rank=3
Neuronal ceroid
lipofuscinosis
(Batten’s
disease, NCL)
Procedure
HuCNS-SC:
human neural
stem cells
Stem Cells Inc. Phase 1b. Single group
assessment
6 6 months–6 yr
M+F. CLN1
or CLN2 mutation. Clinical
diagnosis of NCL
12 months http://clinicaltrials.gov/ct2/show/
study/NCT01238315?term=HuCNS-
SC&rank=2
Stargardt’s disease Retinal pigment
epithelial (RPE)
derived from human
embryonic stem
cells
Advanced Cell
Technology
Inc. (ATC)
Nonrandomized,
single administration
12 Not yet published Not yet published http://www.advancedcell.com/news-
and-media/press-releases/
advanced-cell-technology-receives-
fda-clearance-for-the-first-clinical-trial-
using-embryonic-stem-cel/
Dry age-related
macular
degeneration
(AMD)
Retinal pigment
epithelial (RPE)
derived from human
embryonic stem
cells
Advanced Cell
Technology
Inc. (ATC)
Nonrandomized,
single administration
12 Not yet published Not yet published http://www.actcblog.com/2011/01/
act-receives-fda-clearance-for-clinical-
trials-using-escs-to-treat-amd-afflicts-
10-15-million-americans.html
Type 1 diabetes
mellitus (DM)
PROCHYMAL:
ex vivo adult
mesenchymal
stem cells
Osiris
Therapeutics
Randomized placebo
controlled, double blind.
Phase 2
60 12-35 M+F. Type 1 DM,
at least 1 DM-related
autoantibody. Some
beta-cell function
Not yet published http://clinicaltrials.gov/ct2/show/NCT00690066
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Figure 1. Workflow for Stem Cell-Derived Therapeutic Development
Genetic and phenotypic analysis must be a continuous process throughout
product development, and differentiation status and biodistribution potential
need to be tracked closely to ensure clinical effects are predictable and
controllable.
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is still at an early stage (for reviews on this subject see Nelson
et al., 2010; Nishikawa et al., 2008; Vitale et al., 2011).
As well as iPSCs, other types of adult stem cells, such as
mesenchymal stem cells (MSCs), have been shown to differen-
tiate in vitro into cell lines displaying osteogenic, chondrogenic,
or adipogenic characteristics (Prockop, 1997). Moreover, they
have an immunomodulatory effect on their direct environment
(Aggarwal and Pittenger, 2005), and they are able to secrete
cytokines that are able to initiate intrinsic tissue regenerative
processes (Caplan and Dennis, 2006). However, in contrast to
iPSCs,MSCsare limited in theirdifferentiationcapacity.Neverthe-
less, due to their availability andpotentially beneficial properties—
through either autologous or allogenic donation—MSCs have
been in the spotlight for regenerative medicine for various indica-
tions. As ofMay 5th, 2011, 168 studies have been registered at the
U.S. NIH Clinical Trials registry (http://clinicaltrials.gov/ct2/
results?term=mesenchymal+stem+cells) and 12 studies have
been registered and uploaded onto the EUClinical Trials Register
(https://www.clinicaltrialsregister.eu/ctr-search/).
Clearly, stem cell-based therapies bring with them new safety
challenges that cannot be addressed using standard analytical
procedures developed for low-molecular-weight drugs or other
biopharmaceuticals. A particular difficulty is the ability tomonitor
cell biodistribution, since once administered, the cells may be
essentially indistinguishable from host cells. The ability to track
the therapeutic cells is key to an objective assessment of risk
with respect to inappropriate ectopic tissue formation or of tu-
morigencity. This is especially important where the cells are
administered intravenously, rather than locally, since broad
dissemination is likely to occur. The ability to determine the bio-
distribution of administered cells raises technical issues, as
monitoring the fate of exogenous cells will require the develop-
ment of novel technologies. Furthermore, the detection of mis-
placed cells may necessitate a mechanism for their removal,
which again may not be technically feasible at present. Thus,
there is amajor need for technological advances in biomonitoring
alongside thedevelopment of novelmeans for eliminating admin-
istered cells that become inappropriately located. Eliminating
errant cells is likely to be amore challenging task andmay involve
incorporation of a ‘‘self-destruct’’ mechanism programmed into
the cells to elicit apoptosis in response to a given stimulus.
A major concern with stem cell therapy is that of tumorigenic
potential. Thedelivery of a cell with unlimitedpotential for renewal
and the capacity to differentiate into any human cell type carries
a burden of safety concern not associated with any other class of
treatment.Whether these concerns are justifiedby solid research
support is probably the most significant safety question that
needs to be addressed at the current time. The finding that undif-
ferentiated stem cells, introduced into immunocompromised
animals, are capable of forming teratomas (tumors that are
composed of a haphazard array of somatic cell types, sometimes
arranged into tissues, and normally corresponding to all three
germ layers) emphasizes the importanceof addressing this issue.
Furthermore, if the cells contain genetic abnormalities, these
could potentially develop into teratocarcinomas (Ben-David
and Benvenisty, 2011; Blum and Benvenisty, 2008), which are
tumors composed of a teratoma element together with persisting
undifferentiated stemcells. Thesewouldbeexpected tobehighly620 Cell Stem Cell 8, June 3, 2011 ª2011 Elsevier Inc.malignant, like the corresponding testicular germ cell tumors that
occur in young men.
Another evident safety issue that needs to be tackled by stem
cell therapy providers is that of immunogenicity. Although there
are reports of immune privilege of human embryonic stem cells
(Drukker and Benvenisty, 2004), any foreign cell introduced
into a patient will be subject to immune surveillance (Swijnenburg
et al., 2008). While site of administration andmultiple dosingmay
impact host-induced immunogenicity, a further significant differ-
ence between animal and human studies is that immunosup-
pression can be used in animal studies but may not be medically
acceptable or necessary in trials in patients.
In addition to establishing the efficacy of stem cell therapies,
the successful implementation of novel cell-based treatments
will rely heavily on our ability to resolve these important safety
issues, at both the preclinical and the clinical stages. Every
step in the process of developing stem cell therapies requires
rigorous scrutiny, from the origin of the cells used through
expansion, manipulation, and preclinical evaluation to eventual
engraftment in the host (Halme and Kessler, 2006; National Insti-
tutes of Health, 2006) (see Figure 1).
Importantly, the stem cell therapy field needs to interact at the
level of therapy provider, safety scientist, and drug regulator in
order to define the ‘‘acceptable risk’’ associated with a particular
treatment and to set in place a framework for accurate assess-
ment of that ‘‘risk.’’ In our increasingly risk-averse society it is
easy to err on the side of caution, but it should be acknowledged
that if the safety ‘‘bar’’ is set unreasonably high then the enor-
mous potential and promise of revolutionary medical treatments
may never be realized.The Safety Issues: Preclinical Assessment
In order to minimize patient risk, each stage of the cell therapy
production should be assessed for potential safety concerns,
before introduction to a human subject. This evaluation includes
the manufacturing process itself, as well as the characterization
and formal safety assessment of the finished product.
Manufacturing Consistency
A key area thatmust be addressed is themanufacturing process,
i.e., the need for consistency of manufacture to ensure the
Cell Stem Cell
Perspectivereproducible quality of the product. When preparing cells in vitro
for transplant, it is essential to ensure that the culture is fully
defined and characterized, as the consequences of poor defini-
tion may be far reaching. The importance of this issue from
a regulatory perspective was underlined by the temporary hold
placed by the FDA on Geron’s first-in-human trial of an ESC-
derived treatment for spinal cord injury (GRNOPC1) (Geron,
2009a). One of the concerns raised by the FDA—but subse-
quently allayed by the company—was surety that the manufac-
tured cell product was fully characterized and that the mixtures
of cells were predictable and free from contamination (Geron,
2009b). Clearly, for new treatments targeting clinical conditions
of a less serious nature, the level of stringency of product quality
may be set even higher to avoid the administration of undifferen-
tiated cell contaminants.
Genetic Stability
Most, if not all, cell types acquire chromosomal aberrations
during expansion in culture. As chromosomal aberrations are
a hallmark of human cancer (Hanahan and Weinberg, 2011), it
is very important to perform a detailed analysis of the genome
prior to any cell-based treatment.
The inherent genetic instability of hESCs and iPSCs in culture
has been demonstrated (Baker et al., 2007;Mayshar et al., 2010),
and evidence for the instability of adult stem cells in culture is
also beginning to emerge (Sareen et al., 2009; Ueyama et al.,
2011). Consequently, not only gross karyotype but also detailed
genetic profiling must be undertaken before engraftment into the
host (Stephenson et al., 2010). As somatic cells within the body
are often seen with copy-number variations (CNVs), any minor
aberration that occurs in culture will not necessarily prevent its
clinical use. The functional significance of specific aberrations
that tend to occur in stem cell cultures will need to be assessed
in safety preclinical trials. Acceptable degrees of genetic change
must be established by a thorough examination of subcellular
architecture, including chromosomes, small CNVs, and even
point mutations (Gore et al., 2011; Laurent et al., 2011). Cell-
surface markers and expression of transcription factors, as
well as proliferation capacity and differentiation propensity,
should also be evaluated, as these parameters have been sug-
gested to change during the acquisition of genetic alterations
(Blum and Benvenisty, 2009). Additionally, it is imperative to
assess the heterogeneity of a culture, as the engraftment of
undifferentiated or incorrectly differentiated cells may present
a substantial tumorigenic or immunogenic risk to the recipient
(Baker et al., 2007; Ben-David and Benvenisty, 2011; Fairchild,
2010). As the passage number of a stem cell lines increases,
so too does the potential for chromosomal aberrations to arise
(Hovatta et al., 2010; Maitra et al., 2005). Therefore, minimizing
the culture time might be required in order to decrease the
chance for in vitro genetic alterations.
Dosing and Pharmacokinetics
It is clear that conventional preclinical absorption, distribution,
metabolism, excretion, and toxicity (ADMET) studies cannot
be directly applied to cell-based products where there is
a requirement to track differentiation and migration in vivo.
How therefore can a dosing regimen be meaningfully calculated
and pharmacokinetics/pharmacodynamics (PK/PD) be as-
sessed? Such strategies are normally heavily reliant on risk-
benefit analyses, but it presents a major challenge to makethis analysis when the risks are poorly understood and the
benefits are at present unknown.
Dosing regimens are conventionally based on in vivo dose
response curves, but this method is difficult to translate to cell-
based therapeutics. In determining an appropriate posology, it
will be important to consider both evidence from dose-deter-
mining studies (i.e., it is necessary to consider how to derive
a human equivalent dose; in many cases, animal models of
disease are rodents— therefore, how will we determine how to
scale up doses?) and rationale (comprising scientific and clinical
logic). Dose selection considerations need to include both what
is maximally feasible in the species chosen and the relevance to
the intended human therapeutic dose. Data derived from tests
with syngeneic cells can be useful to establish the dosing princi-
ples but are unlikely to contribute much to quantitative consider-
ations, which are an essential part of determining initial human
doses. It is also important to consider the route of administration
of a product, i.e., whether it is administered systemically or
locally. For example, MSCs are seen to home to sites of injury
but a large proportion will accumulate in the lungs if administered
systemically (Gao et al., 2001; Noort et al., 2002).
When selecting a relevant disease/injury model, it is important
to understand both its attributes and limitations. When a well-
developed animal model is available, evidence for robust
proof-of-concept preclinical test results is valuable and informa-
tive, particularly if the targeted clinical indication requires admin-
istration of the stem cell-based product into a highly vulnerable
anatomical site (Fink, 2009). A major issue for preclinical testing
is the immunological relevance of testing human cells in an
animal model. In certain circumstances, it may be possible to
generate an analogous species-specific product, but this is not
trivial and differences between the cells are likely to exist, which
may limit the utility of this approach. Immunosuppression or
immune-deficient animal models are likely to be employed, but
this approach may mask immune-modulatory or immunotoxico-
logical aspects of the cell-based therapy. Progress is being
madewith humanizedmice but the clinical translatability of these
studies is not yet clear.
Conventional toxicology and safety pharmacology studies rely
on evaluating the effects of small molecules on normal physio-
logical function (clinical observation, organ physiology, blood
chemistry, and hematology) and histology of the organs. Often,
the early studies supporting the first trials in humans are of short
duration (up to 1 month). This timeframe is chosen based on
known PK/PD and the location where the drug will eventually
be eliminated from the system. For some stem cell therapies,
a similar situation may be true and it would be possible to eval-
uate safety by adopting standard methods to determine effects
on physiological function. However, for many cell-based thera-
pies, the goal is to repair or replace damaged tissue specifically
through engraftment. The potential lifetime exposure of a patient
to a treatment the removal of which might not be feasible
requires preclinical studies of significantly longer duration than
are routine. Conventional histopathology is also problematic.
Cell-based therapies will require new approaches in terms of
cell localization and tracking and phenotype/genotype charac-
terization. Furthermore, the potential chronology of tumor or
teratoma formation will necessitate animal studies of substan-
tially longer duration before starting trials in human subjects.Cell Stem Cell 8, June 3, 2011 ª2011 Elsevier Inc. 621
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The design of biodistribution studies conducted in animals must
include a consideration of multiple factors: the methods applied
to cellular detection and their sensitivity, the numbers of indi-
vidual animals to be used, whether both sexes must be used,
or whether a single sex can be considered adequate, whether
a single species is adequate, and the appropriateness of the
route of administration. Where systemic biodistribution of the
product is likely, use of the intravenous route, in addition to
the intended human route of administration, should be consid-
ered. In some instances, it will be feasible to conduct studies
in animals with a condition resembling the human disease, either
induced experimentally or using a strain with a genetic abnor-
mality. However, in many instances it will be the case that human
disease models do not exist: it is conceivable that distribution
may be different between a diseased and nondiseased state
and the relevance of any findings would need to be considered.
Where the therapeutic use is in relation to surgery, it may be that
small animals are not suitable and larger animals such as sheep
or pigs may be required. Generally, the intended human cellular
product should be used in these studies; however, doing so may
require the use of immune-suppressed or immune-compro-
mised animals. The immune system could in turn play a role in
modulating cellular distribution in a patient, complicating the
significance of any findings obtained in an immunodeficient
animal model.
Biodistribution is a complex issue that relates to cell localiza-
tion and migration as well as survival and differentiation status.
At present, there is no single satisfactory method of tracking
the fate of cells in vivo, and limitations of biodistribution assays
arise in terms of sensitivity and limits of detection. In fact, is it
important or even practically possible to track the fate of every
cell over time? One method to do this is through the use of
reporter probe imaging, as discussed by Sallam and Wu
(2010). The use of model cells that have been modified to allow
reporter-based tracking as a surrogate for the therapeutic
product raises two issues. First, if the modified cell was being
used only for the determination of distribution potential, has
the addition of the reporter gene altered the function of the
cell? (That is, how does it relate to the clinical product?) Second,
if the clinical product itself contains the reporter construct, does
the insertion of a transgene into a stem cell line mean that the
stem cell product would have to meet the regulatory criteria for
genetically modified organisms, as well as for cell-based thera-
pies? Clearly, consensus needs to be reached regarding sensi-
tivity of biodistribution assays and the characterization of extra-
neous phenotypes. The discovery of a small number of
undifferentiated cells in the product, or a small number of cells
migrating to ectopic locations, could lead to an assumption of
risk that may not be functionally present and could halt the devel-
opment of an otherwise efficacious product.
Attempts may be made to limit a risk of migration of stem cells
from the target location, for example through the development of
stem cell therapies using devices that are implanted in the target
organ and constrain the stem cell product in this area. The
encapsulation of the stem cell product would enable its future
removal and prevent it from spreading in the patient’s body;
however, it is limited to the treatment of specific diseases,
such as diabetes, in which the encapsulation would not diminish622 Cell Stem Cell 8, June 3, 2011 ª2011 Elsevier Inc.the functionality of the product and thus would not jeopardize its
efficiency (Krishna et al., 2007).
The issues related to biodistribution should not be underesti-
mated, but equally should not be considered insurmountable.
There are emerging technologies in the fields of whole animal
and tissue imaging, cellular biomarkers of phenotypic differenti-
ation, and geneticallymodified tagging of cells that, if successful,
will allow the monitoring of cell-based therapies. These
approaches may offer further methods to address safety
concerns related to biodistribution, and are further discussed
in the safety assays section later in this article.
Immunogenicity and Immunotoxicity
Immunogenicity and immunotoxicity are potentially greater
threats to recipients of cellular products than for conventional
medicines, similar to transplantation therapies. Although the
development of iPSCs holds promise for reducing this risk, the
recent finding by Zhao and colleagues that in mouse iPSCs
can induce a T cell-dependent immune response in syngeneic
recipients (Zhao et al., 2011) shows that caution is warranted
where these cells are used as the starting material. Immunotox-
icity of the clinical product is difficult to assess as studies are
typically run in immune-compromised or -suppressed animals.
An alternative is to generate a species-specific homolog that
may provide supportive data on the risk of immunotoxicity. A
second issue is the potential that a human patient may generate
an immune response to an administered product (immunoge-
nicity). Okamura et al. (2007) attempted to reduce the risk of
immunogenicity for their product by using in vitro assessments
such as NK cell assays, serum cytotoxicity assays, mixed
lymphocyte assays, FACS analysis of cell-surface expression,
and cytokine assay. However, there needs to be some standard-
ization of such assays and appropriate controls are required,
particularly when looking for a negative result. Immunogenicity
may be influenced bymultiple factors including the site of admin-
istration (potential sites of immune privilege e.g., the eye), the
maturation status of the cells, the number of doses, the immuno-
logical basis of the disease, and an aging immune system.
Nonclinical studies with the clinical product may give rise to
a xenogeneic response that may have little relevance to the clin-
ical situation where there is a multidose arm.
The effect of a primed immune environment must be consid-
ered when multiple dosing is indicated; however, this concern
may be more relevant for MSC-based products than for ES/
iPS-derived cells. Moreover, the timeframe for immunogenicity
assessment has to be of long duration, potentially up to the life-
time of a relevant animal model. The product must also be as-
sessed in its final composition and in the absence of any
manufacturing materials such as a scaffold, unless suchmaterial
is part of the therapy. Due consideration must also be given to
the possibility of secondary pharmacology, such as off-target
effects resulting from the secretion of bioactive compounds
from the graft. Similarly, safety pharmacology issues may result
from physiological impairment of organ function due tomigration
of cells to an unwanted site.
Tumorigenicity
The capacity to form teratomas in immunocompromised animals
is a characteristic of pluripotent stem cells (Ben-David and Ben-
venisty, 2011; Blum and Benvenisty, 2007). A donor-derived
brain tumor following neural stem cell transplantation was also
Figure 2. Three Classes of Tumors Could Be Envisaged Arising from
ESCs and Their Derivatives
Initially, pluripotent stem cells produce ‘‘teratomas,’’ which comprise
a haphazard array of somatic cell types, sometimes arranged into tissues, and
corresponding to all three germ layers. These tumors are typically regarded as
benign. However, if undifferentiated stem cells are present in the tumor, then
the tumor is regarded as a teratocarcinoma and would most likely be malig-
nant. A third type of tumor that could arise would be one formed from the
differentiated cells themselves. Such a ‘‘secondary’’ tumor would not have
characteristics of teratomas or teratocarcinomas but would bemost likely akin
to tumors that arise from corresponding tissues in a person or animal.
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Perspectivereported in the literature (Amariglio et al., 2009). However, it is not
yet possible to quantify the tumor risk associated with the intro-
duction of stem cells and stem cell-derived products in vivo.
Where that risk exists, the type of tumor must be considered,
aswell as how susceptible the tumormay be to therapeutic inter-
vention. All these factors contribute to assessing acceptable
risk, as tumorigenicity must be assessed on a case-by-case
basis, dependent on the intended therapeutic indication and
the recipient’s prognosis.
Although most attention has focused on the dangers of tera-
toma or teratocarcinoma development compromising the use
of pluripotent cell derivatives for regenerative medicine, it should
be remembered that it is unlikely that undifferentiated cells will
themselves be deliberately used for transplantation. Thus the
risk posed by these cells is the potential for their contamination
of the preparation of differentiated cells for transplantation. This
risk will be ameliorated by developing appropriate purification
protocols and themeans formonitoring contamination.However,
rather more insidious is the possibility that adult stem cells or
stem cell-derived differentiated cells themselves may be tumori-
genic, perhaps due to mutations acquired during culture of the
parent stem cell. These issues are summarized in Figure 2.
The combination of interspecies differences in tumor develop-
ment between rodents and humans (Anisimov et al., 2005) and
the immunodeficient status of mice used for xenograft models
compromises the translatability of some tumorigenic risks from
animals to man. Ultimately, a collaborative effort between
academia and industry may be the most fruitful approach to
define markers of tumorigenicity. To this end, access to legacy
data on primary hazard identification from studies that were
halted during preclinical testing would greatly assist the risk:be-
nefit analysis for stem cell-based therapies.
The Safety Issues: Clinical assessment
The seminal first-in-human safety trials of stem cell-derived
products to treat spinal injury (Mayor, 2010) and ischemic stroke(Wise, 2010) have had a major impact in this field. Preclinical
tests have been conducted on nude and SCID mice, which
have severely compromised immune systems, but it is unclear
how this model might compare to a human patient and how
the condition of the patient (age, disease, nutrition, gender,
medication, etc.) might affect the efficacy of the introduced cells.
Once the cells have been successfully engrafted, the most
appropriate method of assessing cell migration and bio-
distribution must be employed, and this may be, as discussed
previously, through the employment of validated markers and
new technologies such as imaging.
Obviously, the basic risks of the trial and the therapy must be
assessed, both to patients and to donors (see earlier immune
section), although the net clinical benefit of the product will
evolve through its development life cycle. Due consideration
must be given to timeframes for clinical evaluation and latency,
based on data from animal models, as well as consideration
for the disease status of the recipient. Nevertheless, there is
a lack of data to support the long-term safety of stem cell trans-
plantation, and also it is unclear exactly how clinically manage-
able cell-based adverse events may be. It will therefore be bene-
ficial to establish a registry to centralize records of donors and
recipients.
Finally, an option that should be considered as a fail-safe
mechanism for halting therapy postadministration is through
the deployment of a ‘‘suicide gene’’—a genetic antidote that
could be activated in vivo to ablate all grafted cells, or to select
out all undifferentiated cells. This may take the form of an
apoptosis-regulating gene that could be directed to a safe-
harbor genomic location, as has recently been proposed in
iPSC-based therapies (Papapetrou et al., 2011), although such
genetic modification could potentially alter the characteristics
of the cells. While iPSC-based therapies may be inherently
‘‘safer,’’ since they can be derived from the same patient, the
fact that they have been removed from the host, manipulated
to dedifferentiate or transdifferentiate, often with genetic manip-
ulation, as well as the important emerging evidence of the reten-
tion of the epigenetic status of their former cell type (Kim et al.,
2010; Polo et al., 2010), brings the possibility that they also create
adverse effects that would warrant a means for halting therapy.
Current Assays for Stem Cell Therapy Safety
Assessment
A stem cell therapeutic may contain multiple cell types, depend-
ing on the source of the cells, the purification process, and the
nature of the differentiation process employed. The most
obvious safety risk of such differentiated cultures would be
residual undifferentiated cells that might be tumorigenic (Anisi-
mov et al., 2010; Ben-David and Benvenisty, 2011). Engraftment
of undesired, fully differentiated cell types into an ectopic tissue
might also have detrimental effects. The purity of the differenti-
ated cells can be fully characterized by evaluating various
markers of undifferentiated cells (such as TRA-1-60), markers
of the specific cell type of interest, and markers of undesired
cell types of the same/other lineages. The evaluation of such
markers can be achieved using a quantitative polymerase chain
reaction assay (qPCR), flow cytometry, and immunohistochem-
istry, and a combination of thesemethodsmight provide detailed
knowledge of the purity of the culture (Adewumi et al., 2007;Cell Stem Cell 8, June 3, 2011 ª2011 Elsevier Inc. 623
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clonogenic assays, such as soft agar colony formation assay
(Hamburger, 1987) in the case of pluripotent stem cells and neu-
rosphere formation assay (Reynolds and Weiss, 1992) in the
case of neural stem cells, provide the most direct method to
assess the existence of functional stem cells in a population.
Knowledge of cell purity is crucial, since a mixed cell population
might be beneficial for the pharmacodynamic effect (for
example, mesenchymal stem cells have been suggested to
support the engraftment of other cell types (Cristofanilli et al.,
2011), but residual undifferentiated cells may contribute to the
safety risk, as mentioned above).
Genetic changes in culture must also be evaluated in order to
determine the safety of the therapy. Cells in culture, and stem
cells in particular, accumulate chromosomal aberrations, espe-
cially at high passage numbers (Baker et al., 2007; Mayshar
et al., 2010). These chromosomal abnormalities must be fully
characterized and risk assessed before exposure to a patient.
Analysis of karyotypic changes at passage numbers corre-
sponding to those found in the product would help to assess
safety. Furthermore, where transgenes are used in a product,
the possibility of insertional mutagenesis, and therefore a cancer
risk, must be studied. In addition, as recent studies have demon-
strated that subkaryotypic changes, and even point mutations in
coding regions, might arise in stem cell cultures (Gore et al.,
2011; Hussein et al., 2011; Laurent et al., 2011), more accurate
and expensive methods for the evaluation of the genomic integ-
rity—such as array comparative genomic hybridization (aCGH)
and single-nucleotide polymorphism array (SNP array)—might
also be required.
With regard to animal testing of stem cell products, analysis is
limited by the lifespan of the animal, compared with the lifespan
of a human patient, and longer follow-up studies are likely to be
required for early human stem cell trials as compared to conven-
tional medicines. Such studies in animals would consist of
histology, imaging and behavioral studies, and monitoring of
the interaction of the product with surrounding tissues. Further-
more, testing of the product may be carried out at passage
numbers beyond routine use, to ensure the product remains
safe, particularly with regards to tumor formation and immuno-
genicity. Care should be taken with the use of passage numbers
far in excess of the therapy product as these may carry altered
genetic and phenotypic characteristics that are not clinically
relevant.
Another potential safety issue is that of migration of cells from
the graft. Cells can be tracked using several different methods,
such as genetic labeling, immunohistochemistry, and biolumi-
nescence techniques. An important issue to consider in this re-
gard is the level of sensitivity, and methodological challenges
can increasewhen a large animal model is required. GFP-labeled
cells can be administered to an animal model and the migration
to organs other than the intended target can be monitored using
qPCR and histology (Xiong et al., 2010), although GFP labeling
can potentially alter cellular characteristics. Alternatively, the
cells can be incubated with a labeled perfluorocarbon nanoe-
mulsion before exposure of animals (Hertlein et al., 2011), to
act as a contrast agent for tracing them using nuclear magnetic
resonance (NMR) of organs or magnetic resonance imaging
(MRI) scans of either the whole animal or fixed slices of tissue.624 Cell Stem Cell 8, June 3, 2011 ª2011 Elsevier Inc.Cells can also be tracked using immunohistochemistry and
bioluminescence techniques. Of course, administering human
cells to an animal model makes analysis of biodistribution and
migration very easy to monitor (Ellis et al., 2010). However, it
becomes more complicated to analyze biodistribution of human
cells in a human host. If the cells in the stem cell therapeutic are
adequately characterized, the HLA type should be known and
the host and graft cells can be discriminated based on immuno-
logical characteristics, assuming that imaging technology has
sufficient resolution in human subjects.
Another relevant issue is that preclinical testing of products
designated for closed compartments such as the brain and
CNS has involved the maximum number of cells that can physi-
cally fit in the available tissue space, and clinical trial design has
involved an extrapolation of this cell number based on the phys-
iological difference between the preclinical species and humans
(Redmond et al., 2007). Therefore, techniques to evaluate the
safety of cell-based therapies at the critical stage of transition
from preclinical to clinical trials ought to be developed and stan-
dardized.
Notwithstanding these important preclinical safety assess-
ment issues, there are also concerns at the clinical trial phase
surrounding lack of blinding or placebos, although for some
disease areas, there may need to be new thinking due to the
ethical issues associated with use of placebo cells. There are
also possible issues regarding the effects of concomitant
surgery and/or medication. These require further discussion
and recommendations, which exceed the scope of this article.
Regulation of Stem Cell Therapeutics
The new era of stem cell-based therapies brings new challenges
to drug regulators as well as to safety assessment scientists. In
order to avoid regulatory inconsistencies, which could compro-
mise the translation of novel therapies into clinical usage, it is
essential that a dialog between regulators and therapy providers
be initiated at an early stage. This approach would allow the
identification of potential safety issues and define the expecta-
tion of regulators with respect to risk assessment.
An earlier review in 2006 attempted to apply the current FDA
guidelines for biologics and cell-and-tissue products to
emerging stem cell therapeutics (Halme and Kessler, 2006). As
well as covering some of the issues discussed in this review,
the authors made recommendations for reducing risk to the
recipient from the graft itself, by screening for potentially harmful
or problematic genetic conditions in the donor cells, and by
adequate characterization of the product, particularly since
clonal expansion in vitro may require the use of animal sera or
animal feeder cells. In addition, Figure 3 shows a diagrammatic
representation of an interim regulatory route map from the UK
perspective.
Regulatory experience is rather limited, particularly where
product failure is concerned. Preclinical failures are not brought
to the attention of the regulatory agencies, and as such the regu-
lators have only limited knowledge of the preclinical issues with
product development. Data-sharing consortia may go someway
to addressing these knowledge gaps. Clearly, proof-of-concept
is more important at early stages of development than mecha-
nistic data, but a mechanism is reassuring from a regulatory
standpoint.
Figure 3. Illustrative UK Regulatory Route Map for Stem Cell Research and Manufacture
The UK Medicines and Healthcare Products Agency (MHRA) participated in the production of this regulatory route map for stem cell research and manufacture,
which has been developed by the Department of Health (DoH) with the support of regulatory bodies and the Gene Therapy Advisory Committee (GTAC). This
interim UK regulatory route map is intended to be a reference tool for those who wish to develop a program of stem cell research and manufacture ultimately
leading to clinical application. A web tool to apply this in practice, using a decision-tree approach, is available at http://www.sc-toolkit.ac.uk/home.cfm. Other
abbreviations: HTA, human tissue authority; NHS, National Health Service; GLP, Good Laboratory Practice; GMP, GoodManufacturing Practice; R&D, Research
and Development; HFEA, The Human Fertilisation and Embryology Authority; REC, Research Ethics Committee; ATMP, Advanced Therapy Medicinal Products;
EMEA, European Medicines Agency; EudraCT, a database of all clinical trials commencing in the European Union from May 1, 2004 onward. (See http://www.
mhra.gov.uk/Howweregulate/Medicines/Medicinesregulatorynews/CON041337.)
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European Medicines Agency (EMA) Committee for Advanced
Therapies (CAT), which was set up in 2008 to regulate new ther-
apies such as cell-based therapies and is made up of European
regulators, academics, clinicians, companies, and patient socie-
ties. As a multidisciplinary committee, the CAT is designed to
cover a wide range of aspects of all advanced therapies,
including stem-cell based therapies. Any new therapies are
authorized centrally, but the decision as to whether a member
state actually permits the use of the therapy is made at a national
level (e.g., Germany, in which treatment with medicinal products
containing embryonic stem cells is not permitted). Under-
standing and learning from this type of approach may be valu-
able in deciding how to address the issue of stem cell regulation.
Regulatory Safety Requirements for Stem Cell
Therapeutics
For stem cell therapies, a regulatory approach based on conven-
tional pharmaceutical products is not appropriate. Licensing
decisions aremade on a case-by-case basis, using a risk-benefitapproach. Ultimately, in terms of safety, there is no distinction
between small-molecule and cell-based therapies—they all
need to meet acceptable standards of quality, safety, and effi-
cacy before they can be widely used. Obviously, a stem cell
product must be produced under Good Manufacturing Practice,
with operations fully characterized and records and standard
operating procedures in place. The product must also be
adequately characterized. Knowledge of the purity of the product
must be known, since extraneous phenotypes may either influ-
ence efficacy or contribute a significant safety risk. Any chromo-
somal abnormalities must be well characterized, in case there is
a riskof contributing to tumor formation.While animal data should
be supplied, where appropriate and informative, nonhuman
primates should be used only if they are the best model.
The general consensus of regulatory agencies with regard to
tracking biodistribution is to favor pragmatism as opposed to
exhaustive analysis. For example, MRI and 3D imaging gener-
ates a huge amount of data, which can be difficult to interpret
without good bioinformatics and systems analysis. RegulatorsCell Stem Cell 8, June 3, 2011 ª2011 Elsevier Inc. 625
Cell Stem Cell
Perspectiverequire that safety consideration is part of the manufacturing
process as a whole. If the manufacturing process is changed
to account for an issue with safety, the product must be proven
to remain safe and efficacious.
Dose-escalation studies are difficult to carry out using cell-
based therapeutics, but there must be a clear evidence-based
rationale underlying choice of dose in clinical trials. To some
extent, the strategy will depend on the product. The risks asso-
ciated with the procedure to administer a cell-based therapeutic
must be fully understood, i.e., the route of application, duration
of exposure if this is not indefinite, and need for repeat applica-
tions. Furthermore, any device used for implantation needs to be
approved for use in patients.
After characterization in animal studies and allometric scaling
to human requirements, it is acknowledged that formal dose-
escalation studies in humans might not always be feasible,
although the bespoke nature of different cell-based therapies
suggests that this may not always be the case. Lessons may
be learned from the approaches used in the biologics/antibody
world. If such studies are required, then they would be for the
purposes of both tolerability and efficacy with the appropriate
indices and biomarkers.
Regulatory Support
Communication is a key cornerstone of regulatory support. We
particularly highlight the importance of establishing a dialog
with the International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for Human
Use (ICH), as well as improving communications with health
authorities. In particular, improved collaborations between
production and preclinical testing specialists, to ensure compa-
rability of product or adequate testing where a product changes,
may help streamline safety evaluations.
Increasingly, there are examples of industry and regulatory
collaborations and consortia, such as the European Innovative
Medicines Initiative (IMI), that adopt a precompetitive data-
sharing approach to facilitate development of new safety evalu-
ation methods. Nevertheless, only positive examples are taken
forward into clinical development, meaning that the examples
that fail are not publicized and information is not shared with
others. Early interaction between regulatory agencies, therapy
developers, and drug safety scientists is important in this
evolving field, since clear regulatory guidelines help in planning
product development. Precompetitive data-sharing approaches
can involve the use of third-party organizations that act as
a central and anonymous repository for storage and analysis of
data, before sharing with the consortia members. Furthermore,
discussions with regulators can assist companies working on
individual development programs. As a corollary, companies
that have been through the regulatory process before may
have an insight into current regulatory requirements, and sharing
of this type of information could also form an industry precompe-
titive approach.Proposals
To expedite the advancement of the field of safety assessment of
stem cell therapeutics, we would submit the following proposals:
d Collaborations between industry, academia, and regula-
tory authorities should be undertaken at every opportunity,626 Cell Stem Cell 8, June 3, 2011 ª2011 Elsevier Inc.using current centers of excellence, leading to the estab-
lishment of cross-institution expert cell-based therapy
safety groups.
d Consortia that adopt a precompetitive data-sharing
approach to facilitate development of new safety evalua-
tion methods should be encouraged. Although data
sharing can be challenging in practice, there are already
emerging examples, such as through the IMI strategy
described above.
d A centralized registry of donors and recipients should be
established in order to best manage adverse events.
d Efforts need to be made to educate the public and media
on the benefits and risks of stem cell-based therapies,
and to explain issues rationally. This type of approach is
key for articulating the notion of ‘‘acceptable risk’’ for
a novel therapy.
d Research efforts that prioritize the following areas should
be facilitated:
1. Model systems. Research is required into the estab-
lishment of relevant animal models to improve preclin-
ical testing. The development and inclusion of positive
and negative control cell lines, for efficacy and/or
toxicity, wherever possible, would add value to animal
data.
2. Safety and efficacy biomarkers. There is an immediate
and pressing need to establish appropriate biomarkers
for each stage of the development process. There is
also a need for funding of research into markers of
cell function, differentiation, and migration in vivo.
3. Immunogenicity/Immunotoxicity. The risk of immuno-
toxicity is poorly characterized at present, largely
due to a paucity of appropriate preclinical models,
and further research is necessary to elucidate the
interactions of grafted cells with the host immune
system.
4. Tumorogenicity. Tumorigenesis is also of great
concern, and we suggest that research into the possi-
bility of employing ‘‘stop methods’’ would be of great
value as a means of ablating all grafted cells. In addi-
tion, marker panels for tumorigenic risk both pre- and
postengraftment would be highly informative.
In summary, it is not clear whether the state of our under-
standing is sufficient to appraise the safety of these therapies
in a comprehensive manner, and we therefore require further
sensitive and robust approaches in bioanalysis to monitor
them. At a broader level, it is also important to raise the question
of whether we are setting a higher bar for the clinical implemen-
tation of stem cell-derived therapeutics than we currently apply
for other types of cellular therapy. There is a danger that if
perfection is a prerequisite for beginning, then we will never
begin. Ultimately, while stem cell therapy is an area of rapid
advancement, the science of stem cell safety assessment
must also evolve, not to hinder progress, but to support, guide,
and expedite patient treatment. The development of such tech-
nology is necessary to ensure that we can proceed with appro-
priate safeguards in place and allow that stem cell-based ther-
apeutic approaches develop in a way that benefits society
overall.
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